SRR1079168
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.530
- INFLAMMATORY_RESPONSE+0.520
- ALLOGRAFT_REJECTION+0.517
- INTERFERON_ALPHA_RESPONSE+0.514
- INTERFERON_GAMMA_RESPONSE+0.502
- TNFA_SIGNALING_VIA_NFKB+0.431
- ANGIOGENESIS+0.397
- COAGULATION+0.396
- IL2_STAT5_SIGNALING+0.370
- COMPLEMENT+0.352
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.511
- HEDGEHOG_SIGNALING-0.449
- MYC_TARGETS_V2-0.436
- DNA_REPAIR-0.385
- UNFOLDED_PROTEIN_RESPONSE-0.338
- NOTCH_SIGNALING-0.260
- UV_RESPONSE_DN-0.259
- MYC_TARGETS_V1-0.224
- PROTEIN_SECRETION-0.223
- ADIPOGENESIS-0.216
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1370173 | GTEX | — | 0.943 |
| 2 | SRR1387989 | GTEX | — | 0.939 |
| 3 | SRR1315994 | GTEX | — | 0.935 |
| 4 | SRR1464411 | GTEX | — | 0.933 |
| 5 | SRR1323807 | GTEX | — | 0.933 |
| 6 | SRR1441701 | GTEX | — | 0.929 |
| 7 | SRR1416889 | GTEX | — | 0.923 |
| 8 | SRR615934 | GTEX | — | 0.921 |
| 9 | SRR1073755 | GTEX | — | 0.920 |
| 10 | SRR1468403 | GTEX | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.517 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.514 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.502 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.431 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.397 | Remibrutinib | — uncovered |
| COAGULATION | 0.396 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| COMPLEMENT | 0.352 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.333 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.302 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.296 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.218 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.154 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.149 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.134 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.129 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |